[CTRV] ContraVir Pharmaceuticals Inc


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 34.81 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.35 Change: 0 (0%)
Ext. hours: Change: 0 (0%)

chart CTRV

Refresh chart

Fundamental Ratios
Shares Outstanding32.23 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV4.42 Price/Cash Per Share
Price/Free Cash Flow-25.24 ROA-48.33% ROE-58.23% ROI
Current Ratio5.79 Quick Ratio Long Term Debt/Equity Debt Ratio0.2
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities12.5 M Cash From Investing Activities-80 K Cash From Operating Activities-5.33 M Gross Profit
Net Profit-4.4 M Operating Profit-4.4 M Total Assets9.5 M Total Current Assets9.36 M
Total Current Liabilities1.62 M Total Debt Total Liabilities1.62 M Total Revenue
Technical Data
High 52 week25.41 Low 52 week0.43 Last close8.16 Last change-3.88%
RSI51.26 Average true range9.36 Beta-2.19 Volume797.1 K
Simple moving average 20 days-18.28% Simple moving average 50 days-43.47% Simple moving average 200 days2.58%
Performance Data
Performance Week-8.86% Performance Month-50.02% Performance Quart-51.48% Performance Half1557.52%
Performance Year239.79% Performance Year-to-date1468.27% Volatility daily14.19% Volatility weekly31.73%
Volatility monthly65.03% Volatility yearly225.29% Relative Volume435.32% Average Volume3.01 M
New High New Low


2019-07-29 16:15:00 | Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH

2019-07-22 16:02:27 | 13 Disastrous Stocks That Could Get Even Worse

2019-07-22 14:00:00 | ContraVir Pharmaceuticals Announces Name Change to Hepion Pharmaceuticals, Inc.; Trading Symbol Change to “HEPA”

2019-06-27 08:00:00 | ContraVir Pharmaceuticals Submits IND Application for CRV431 for NASH

2019-06-21 17:00:12 | Advice For New Traders When Momentum Dries Up

2019-06-21 09:57:15 | ContraVir Rebounds From Record Low On Positive FDA Feedback

2019-06-21 07:31:00 | ContraVir's stock rockets off record low after 'positive feedback' on pre-IND for NASH

2019-06-21 07:18:48 | The Daily Biotech Pulse: ContraVir's Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy

2019-06-19 10:41:00 | ContraVir’s stock suffers record plunge after seesaw week of upbeat drug studies, mistaken filings and withdrawals of withdrawals

2019-06-18 15:11:00 | ContraVir’s stock plunges after seesaw week of upbeat drug studies, mistaken filings and withdrawals of withdrawals

2019-06-18 08:45:00 | ContraVir Pharmaceuticals, Inc. Announces Pricing of $15.6 Million Public Offering

2019-06-17 13:50:50 | ContraVir Moves Higher After NASH Drug Shows 100% Efficacy In Fibrosis Prevention

2019-06-17 08:00:00 | Compelling Positive Results Reported from Human Liver Experiments with ContraVir Pharmaceuticals’ NASH Drug Candidate

2019-06-11 14:29:14 | Why Low-Float, Thinly Traded ContraVir Pharma's Rally Is Continuing

2019-06-11 08:30:00 | ContraVir Pharmaceuticals Announces Publication of CRV431 Data from Experimental Model of Hepatitis B

2019-06-07 14:27:20 | Why ContraVir Pharmaceuticals CTRV Is Skyrocketing Today

2019-06-06 11:44:25 | ContraVir Rallies As NASH Drug Shows Efficacy In Preclinical Study

2019-06-06 08:00:00 | ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis

2019-05-31 08:00:00 | ContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split

2019-05-06 08:00:00 | ContraVir Pharmaceuticals Receives Positive Nasdaq Listing Decision

2019-04-29 08:30:00 | ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity Conference

2019-04-26 08:02:57 | The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug

2019-04-25 09:02:38 | ContraVir Pharmaceuticals, Inc. Announces Pricing of $2.14 Million Public Offering

2019-04-11 08:00:00 | ContraVir Pharmaceuticals to Present CRV431 Phase 1 Data at the International Liver Congress™

2019-04-05 14:14:57 | Again, Durham pharma loses a drug development partner

2019-03-04 14:01:00 | ContraVir Pharmaceuticals Announces Panel Participation at 31st Annual ROTH Conference

2019-01-16 08:24:33 | The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

2019-01-15 18:25:00 | ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders

2018-11-27 16:30:00 | ContraVir Pharmaceuticals to Present CRV431 Preclinical Data at the Anti-Fibrotic Drug Development Summit

2018-11-06 08:00:00 | ContraVir Pharmaceuticals to Present Two Posters at The Liver Meeting® 2018, Hosted by the American Association for the Study of Liver Diseases

2018-10-30 08:05:00 | Leading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of Directors

2018-10-30 08:00:00 | ContraVir Pharmaceuticals Completes Final Cohort Dosing in CRV431 Drug-Drug Interaction Study

2018-10-15 08:01:00 | Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team

2018-10-03 08:00:00 | Robert Foster Appointed Acting Chief Executive Officer of ContraVir Pharmaceuticals, Inc.

2018-09-18 09:00:00 | ContraVir Pharmaceuticals Announces Completion of Phase 1 with CRV431

2018-08-30 09:00:00 | ContraVir Pharmaceuticals Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018

2018-08-07 09:00:00 | ContraVir Pharmaceuticals Completes Data Analysis of Second Cohort in Part 1 of the Phase 1/2a Study of CRV431

2018-08-06 15:30:00 | ContraVir Pharmaceuticals Provides an Update to Corporate Objectives

2018-07-24 08:15:47 | ContraVir Stock Rose on Clinical Trial Progress Report

2018-07-23 08:00:00 | ContraVir Pharmaceuticals Reports Progress in Phase 1/2A Trial of CRV431

2018-07-10 08:35:00 | Live Investor Conference & Webinar: NASDAQ and OTC companies to present live on July 12th

2018-07-05 08:35:00 | ContraVir Pharmaceuticals to Present at Virtual Investor Conference

2018-06-29 08:00:00 | ContraVir Pharmaceuticals Announces $10.8 Million in Expected Gross Proceeds from Recently Expired Rights Offering

2018-06-25 08:00:00 | ContraVir Pharmaceuticals Initiates Dosing of CRV431 in First In-Human Trial

2018-06-21 08:00:00 | ContraVir Pharmaceuticals Announces Data on Optimized Formulation of TXL™

2018-06-20 12:30:00 | ContraVir Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

2018-06-18 16:01:00 | ContraVir Pharmaceuticals to Provide Corporate, Business and Clinical Updates

2018-06-14 08:23:26 | ContraVir Pharmaceuticals Announces the Approval of the IND and Initiation of the Clinical Development Program of CRV431 in the United States

2018-06-12 12:17:03 | ContraVir Pharmaceuticals Reminds Investors of Today’s Deadline to be a Shareholder of Record

2018-06-05 09:00:00 | ContraVir Pharmaceuticals Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering